{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:50:04Z","timestamp":1791579004808,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.yrtph.2026.106267","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:13:04Z","timestamp":1790896384000},"page":"106267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New approach methodologies in pharmaceutical development: Survey insights on adoption, infrastructure, and the path to broader implementation"],"prefix":"10.1016","volume":"173","author":[{"given":"Jessica C.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Morenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodaran","family":"Annamalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3853-1399","authenticated-orcid":false,"given":"Danielle","family":"Elbirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna N.","family":"Gaskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-8957","authenticated-orcid":false,"given":"Dawn S.Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Orsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Sedgwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Spatzenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106267_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104662","article-title":"An FDA\/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs)","volume":"114","author":"Avila","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106267_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/dmd.123.001510","article-title":"The current status and use of microphysiological systems by the pharmaceutical industry: the International Consortium for Innovation and Quality microphysiological systems affiliate survey and commentary","volume":"52","author":"Baker","year":"2024","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2026.106267_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2025.109279","article-title":"New approach methodologies in human health risk assessment across European regulatory frameworks: status quo, barriers and drivers for regulatory acceptance and use","volume":"196","author":"Bearth","year":"2025","journal-title":"Environ. Int."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106267_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41573-025-01182-9","article-title":"Application of new approach methodologies for nonclinical safety assessment of drug candidates","volume":"24","author":"Beilmann","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106267_bib5","first-page":"451","article-title":"Considerations from the pharmaceutical industry (IQ MPS Affiliate) workshop on animal microphysiological systems and 3Rs in drug development","volume":"42","author":"Devine","year":"2025","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106267_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.namjnl.2026.100086","article-title":"3Rs at the european medicines agency: past and future activities","volume":"2","author":"Empl","year":"2026","journal-title":"NAM J."},{"key":"10.1016\/j.yrtph.2026.106267_bib7","series-title":"Reflection Paper on the Current Regulatory Testing Requirements for Medicinal Products for Human Use and Opportunities for Implementation of the 3Rs \u2014 Draft (EMA\/CHMP\/CVMP\/3Rs\/742466\/2015 Rev. 1)","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106267_bib9","series-title":"Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106267_bib11","series-title":"Roadmap to Reducing Animal Testing in Preclinical Safety Studies","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106267_bib12","series-title":"General Considerations for the Use of New Approach Methodologies in Drug Development","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106267_bib13","series-title":"Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106267_bib14","series-title":"Potential Approaches to Drive Future Integration of New Alternative Methods for Regulatory Decision-Making","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106267_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.7074","article-title":"Eliminating unnecessary animal testing","author":"H\u00f8eg","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.yrtph.2026.106267_bib16","series-title":"ICH Reflection Paper","article-title":"International harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106267_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.namjnl.2026.100085","article-title":"Never-ending acronym madness: proposing a harmonized definition for NAMs","volume":"2","author":"LaFollette","year":"2026","journal-title":"NAM J."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106267_bib19","first-page":"204","article-title":"Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare","volume":"42","author":"Marx","year":"2025","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106267_bib20","article-title":"Collection of alternative methods for regulatory application (CAMERA)","year":"2025","journal-title":"Nation. Institute Environ. Health Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106267_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106267_bib22","series-title":"Test Guideline No. 439: in Vitro Skin Irritation \u2014 Reconstructed Human Epidermis Test Method","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106267_bib23","series-title":"Test Guideline No. 437: Bovine Corneal Opacity and Permeability Test Method","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106267_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105904","article-title":"A call to action: advancing new approach methodologies (NAMs) in regulatory toxicology through a unified framework for validation and acceptance","volume":"162","author":"Ouedraogo","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106267_bib25","first-page":"714","article-title":"Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs)","volume":"42","author":"Oyetade","year":"2025","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106267_bib26","series-title":"Pharmaceuticals and Medical Devices Agency, May 2026","article-title":"Considerations for the general toxicity evaluation of monoclonal antibodies","year":"2026"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106267_bib27","first-page":"224","article-title":"Opportunities and challenges for human microphysiological systems in drug development","volume":"42","author":"Rahman","year":"2025","journal-title":"ALTEX"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106267_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/d41573-025-00038-6","article-title":"Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective","volume":"24","author":"Robertson","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106267_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104328","article-title":"Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment","volume":"30","author":"Shenton","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yrtph.2026.106267_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.toxlet.2025.02.011","article-title":"Modernizing toxicology: the importance of accessible NAM training","volume":"406","author":"Slankster-Schmierer","year":"2025","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106267_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41573-021-00323-0","article-title":"Adoption of organ-on-chip platforms by the pharmaceutical industry","volume":"20","author":"Vulto","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106267_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/10915818251384270","article-title":"FDA\/CDER\/OND experience with new approach methodologies (NAMs)","volume":"45","author":"Yao","year":"2026","journal-title":"Int. J. Toxicol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:07Z","timestamp":1791576367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":29,"alternative-id":["S0273230026002400"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106267","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approach methodologies in pharmaceutical development: Survey insights on adoption, infrastructure, and the path to broader implementation","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106267"}}